Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012–2013

Detalhes bibliográficos
Autor(a) principal: Meijer, Adam
Data de Publicação: 2014
Outros Autores: Andrade, Helena Rebelo de, Correia, Vanessa, Besselaar, Terry, Drager-Dayal, Renu, Fry, Alicia, Gregory, Vicky, Gubareva, Larisa, Kageyama, Tsutomu, Lackenby, Angie, Lo, Janice, Odagiri, Takato, Pereyaslov, Dmitriy, Siqueira, Marilda Agudo Mendonça Teixeira de, Takashita, Emi, Tashiro, Masato, Wang, Dayan, Wong, Sun, Zhang, Wenqing, Daniels, Rod S., Hurt, Aeron C.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/10882
Resumo: National Institute for Public Health and the Environment. Bilthoven, The Netherlands.
id CRUZ_a756c44724d677a7358a3be28b2231d7
oai_identifier_str oai:www.arca.fiocruz.br:icict/10882
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Meijer, AdamAndrade, Helena Rebelo deCorreia, VanessaBesselaar, TerryDrager-Dayal, RenuFry, AliciaGregory, VickyGubareva, LarisaKageyama, TsutomuLackenby, AngieLo, JaniceOdagiri, TakatoPereyaslov, DmitriySiqueira, Marilda Agudo Mendonça Teixeira deTakashita, EmiTashiro, MasatoWang, DayanWong, SunZhang, WenqingDaniels, Rod S.Hurt, Aeron C.2015-06-17T12:05:25Z2015-06-17T12:05:25Z2014MEIJER, Adam et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013. Antiviral Research, v. 110, p. 31-41, 2014.0166-3542https://www.arca.fiocruz.br/handle/icict/1088210.1016/j.antiviral.2014.07.001engElsevierGlobal update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012–2013info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleNational Institute for Public Health and the Environment. Bilthoven, The Netherlands.Instituto Nacional de Saúde. Lisboa Portugal / Universidade de Lisboa. Faculdade de Farmácia. Lisboa, Portugal.Instituto Nacional de Saúde. Lisboa Portugal / Universidade de Lisboa. Faculdade de Farmácia. Lisboa, Portugal.World Health Organization. Global Influenza Programme. Geneva, Switzerland.Public Health Laboratory Centre. Hong Kong, China.World Health Organization Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza. Centers for Disease Control and Prevention. Atlanta. USA.World Health Organization Collaborating Centre for Reference and Research on Influenza. MRC-National Institute for Medical Research. London, UK.World Health Organization Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza. Centers for Disease Control and Prevention. Atlanta. USA.World Health Organization Collaborating Centre for Reference and Research on Influenza.National Institute of Infectious Diseases. Tokyo. Japan.Public Health England Colindale. London, United Kingdom.Public Health Laboratory Centre. Hong Kong, China.World Health Organization Collaborating Centre for Reference and Research on Influenza.National Institute of Infectious Diseases. Tokyo. Japan.World Health Organization Regional Office for Europe. Division of Communicable Diseases, Health Security, & Environment. Copenhagen, Denmark.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. WHO/NIC. Laboratório de Vírus Respiratório e Sarampo. Rio de Janeiro, RJ, Brasil.World Health Organization Collaborating Centre for Reference and Research on Influenza.National Institute of Infectious Diseases. Tokyo. Japan.World Health Organization Collaborating Centre for Reference and Research on Influenza.National Institute of Infectious Diseases. Tokyo. Japan.World Health Organization Collaborating Centre for Reference and Research on Influenza,. Chinese National Influenza Center. National Institute for Viral Disease Control and Prevention. Chinese Center for Disease Control and Prevention. Beijing, China.Public Health Laboratory Centre. Hong Kong, China.Public Health Laboratory Centre. Hong Kong, China.World Health Organization Collaborating Centre for Reference and Research on Influenza. MRC-National Institute for Medical Research. London, UK.World Health Organization Collaborating Centre for Reference and Research on Influenza.Peter Doherty Institute for Infection and Immunity. Melbourne, Australia / University of Melbourne. Melbourne School of Population and Global Health. Melbourne, Australia.Emergence of influenza viruses with reduced susceptibility to neuraminidase inhibitors (NAIs) is sporadic, often follows exposure to NAIs, but occasionally occurs in the absence of NAI pressure. The emergence and global spread in 2007/2008 of A(H1N1) influenza viruses showing clinical resistance to oseltamivir due to neuraminidase (NA) H275Y substitution, in the absence of drug pressure, warrants continued vigilance and monitoring for similar viruses. Four World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza (WHO CCs) tested 11,387 viruses collected by WHO-recognized National Influenza Centres (NIC) between May 2012 and May 2013 to determine 50% inhibitory concentration (IC50) data for oseltamivir, zanamivir, peramivir and laninamivir. The data were evaluated using normalized IC50 fold-changes rather than raw IC50 data. Nearly 90% of the 11,387 viruses were from three WHO regions: Western Pacific, the Americas and Europe. Only 0.2% (n = 27) showed highly reduced inhibition (HRI) against at least one of the four NAIs, usually oseltamivir, while 0.3% (n = 39) showed reduced inhibition (RI). NA sequence data, available from the WHO CCs and from sequence databases (n = 3661), were screened for amino acid substitutions associated with reduced NAI susceptibility. Those showing HRI were A(H1N1)pdm09 with NA H275Y (n = 18), A(H3N2) with NA E119V (n = 3) or NA R292K (n = 1) and B/Victoria-lineage with NA H273Y (n = 2); amino acid position numbering is A subtype and B type specific. Overall, approximately 99% of circulating viruses tested during the 2012–2013 period were sensitive to all four NAIs. Consequently, these drugs remain an appropriate choice for the treatment and prophylaxis of influenza virus infections.Influenza virusAntiviral resistanceNeuraminidase inhibitorsOseltamivirGlobal analysisNormalization using fold-change dataOseltamivirInfluenza humanaNeuraminidaseesistência a Medicamentosinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txttext/plain1914https://www.arca.fiocruz.br/bitstream/icict/10882/1/license.txt7d48279ffeed55da8dfe2f8e81f3b81fMD51ORIGINALmarilda_siqueira2etal_IOC_2014.pdfapplication/pdf510166https://www.arca.fiocruz.br/bitstream/icict/10882/2/marilda_siqueira2etal_IOC_2014.pdff06f089e5e829e4c7551ddea78b9c0fcMD52TEXTmarilda_siqueira2etal_IOC_2014.pdf.txtmarilda_siqueira2etal_IOC_2014.pdf.txtExtracted texttext/plain57034https://www.arca.fiocruz.br/bitstream/icict/10882/3/marilda_siqueira2etal_IOC_2014.pdf.txtc258ee3cf818a98496896094c6bb36ecMD53icict/108822022-06-24 13:08:43.404oai:www.arca.fiocruz.br:icict/10882TElDRU7Dh0EgREUgRElTVFJJQlVJw4fDg08gTsODTy1FWENMVVNJVkEKCkFvIGNvbmNvcmRhciBlIGFjZWl0YXIgZXN0YSBsaWNlbsOnYSB2b2PDqiAoYXV0b3Igb3UgZGV0ZW50b3IgZG9zIGRpcmVpdG9zIGF1dG9yYWlzKToKCmEpIERlY2xhcmEgcXVlIGNvbmhlY2UgYSBwb2zDrXRpY2EgZGUgY29weXJpZ2h0IGRhIGVkaXRvcmEgZG8gc2V1IGRvY3VtZW50by4KCmIpIERlY2xhcmEgcXVlIGNvbmhlY2UgZSBhY2VpdGEgYXMgRGlyZXRyaXplcyBwYXJhIG8gUmVwb3NpdMOzcmlvIEluc3RpdHVjaW9uYWwgZGEgRnVuZGHDp8OjbyBPc3dhbGRvIENydXogKEZJT0NSVVopLgoKYykgQ29uY2VkZSDDoCBGSU9DUlVaIG8gZGlyZWl0byBuw6NvLWV4Y2x1c2l2byBkZSBhcnF1aXZhciwgcmVwcm9kdXppciwgY29udmVydGVyIChjb21vIGRlZmluaWRvIGEgc2VndWlyKSwgY29tdW5pY2FyCiAKZS9vdSBkaXN0cmlidWlyIG5vIFJlcG9zaXTDs3JpbyBkYSBGSU9DUlVaLCBvIGRvY3VtZW50byBlbnRyZWd1ZSAoaW5jbHVpbmRvIG8gcmVzdW1vL2Fic3RyYWN0KSBlbSBmb3JtYXRvIGRpZ2l0YWwgb3UgCgpwb3IgcXVhbHF1ZXIgb3V0cm8gbWVpby4KCmQpIERlY2xhcmEgcXVlIGF1dG9yaXphIGEgRklPQ1JVWiBhIGFycXVpdmFyIG1haXMgZGUgdW1hIGPDs3BpYSBkZXN0ZSBkb2N1bWVudG8gZSBjb252ZXJ0w6otbG8sIHNlbSBhbHRlcmFyIG8gc2V1IGNvbnRlw7pkbywgCgpwYXJhIHF1YWxxdWVyIGZvcm1hdG8gZGUgYXJxdWl2bywgbWVpbyBvdSBzdXBvcnRlLCBwYXJhIGVmZWl0b3MgZGUgc2VndXJhbsOnYSwgcHJlc2VydmHDp8OjbyAoYmFja3VwKSBlIGFjZXNzby4KCmUpIERlY2xhcmEgcXVlIG8gZG9jdW1lbnRvIHN1Ym1ldGlkbyDDqSBvIHNldSB0cmFiYWxobyBvcmlnaW5hbCwgZSBxdWUgZGV0w6ltIG8gZGlyZWl0byBkZSBjb25jZWRlciBhIHRlcmNlaXJvcyBvcyBkaXJlaXRvcyAKCmNvbnRpZG9zIG5lc3RhIGxpY2Vuw6dhLiBEZWNsYXJhIHRhbWLDqW0gcXVlIGEgZW50cmVnYSBkbyBkb2N1bWVudG8gbsOjbyBpbmZyaW5nZSBvcyBkaXJlaXRvcyBkZSBxdWFscXVlciBvdXRyYSBwZXNzb2Egb3UgZW50aWRhZGUuCgpmKSBEZWNsYXJhIHF1ZSwgbm8gY2FzbyBkbyBkb2N1bWVudG8gc3VibWV0aWRvIGNvbnRlciBtYXRlcmlhbCBkbyBxdWFsIG7Do28gZGV0w6ltIG9zIGRpcmVpdG9zIGRlIGF1dG9yLCBvYnRldmUgYSBhdXRvcml6YcOnw6NvIAoKaXJyZXN0cml0YSBkbyByZXNwZWN0aXZvIGRldGVudG9yIGRlc3NlcyBkaXJlaXRvcywgcGFyYSBjZWRlciBhIEZJT0NSVVogb3MgZGlyZWl0b3MgcmVxdWVyaWRvcyBwb3IgZXN0YSBMaWNlbsOnYSBlIGF1dG9yaXphciBhIAoKdXRpbGl6w6EtbG9zIGxlZ2FsbWVudGUuIERlY2xhcmEgdGFtYsOpbSBxdWUgZXNzZSBtYXRlcmlhbCBjdWpvcyBkaXJlaXRvcyBzw6NvIGRlIHRlcmNlaXJvcyBlc3TDoSBjbGFyYW1lbnRlIGlkZW50aWZpY2FkbyBlIHJlY29uaGVjaWRvIAoKbm8gdGV4dG8gb3UgY29udGXDumRvIGRvIGRvY3VtZW50byBlbnRyZWd1ZS4KCmcpIFNFIE8gRE9DVU1FTlRPIEVOVFJFR1VFIMOJIEJBU0VBRE8gRU0gVFJBQkFMSE8gRklOQU5DSUFETyBPVSBBUE9JQURPIFBPUiBPVVRSQSBJTlNUSVRVScOHw4NPIFFVRSBOw4NPIEEgRklPQ1JVWiwgREVDTEFSQSBRVUUgQ1VNUFJJVSAKClFVQUlTUVVFUiBPQlJJR0HDh8OVRVMgRVhJR0lEQVMgUEVMTyBSRVNQRUNUSVZPIENPTlRSQVRPIE9VIEFDT1JETy4gQSBGSU9DUlVaIGlkZW50aWZpY2Fyw6EgY2xhcmFtZW50ZSBvKHMpIG5vbWUocykgZG8ocykgYXV0b3IoZXMpIGRvcyAKCmRpcmVpdG9zIGRvIGRvY3VtZW50byBlbnRyZWd1ZSBlIG7Do28gZmFyw6EgcXVhbHF1ZXIgYWx0ZXJhw6fDo28sIHBhcmEgYWzDqW0gZG8gcHJldmlzdG8gbmEgYWzDrW5lYSBjKS4KRepositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352022-06-24T16:08:43Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012–2013
title Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012–2013
spellingShingle Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012–2013
Meijer, Adam
Influenza virus
Antiviral resistance
Neuraminidase inhibitors
Oseltamivir
Global analysis
Normalization using fold-change data
Oseltamivir
Influenza humana
Neuraminidase
esistência a Medicamentos
title_short Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012–2013
title_full Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012–2013
title_fullStr Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012–2013
title_full_unstemmed Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012–2013
title_sort Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012–2013
author Meijer, Adam
author_facet Meijer, Adam
Andrade, Helena Rebelo de
Correia, Vanessa
Besselaar, Terry
Drager-Dayal, Renu
Fry, Alicia
Gregory, Vicky
Gubareva, Larisa
Kageyama, Tsutomu
Lackenby, Angie
Lo, Janice
Odagiri, Takato
Pereyaslov, Dmitriy
Siqueira, Marilda Agudo Mendonça Teixeira de
Takashita, Emi
Tashiro, Masato
Wang, Dayan
Wong, Sun
Zhang, Wenqing
Daniels, Rod S.
Hurt, Aeron C.
author_role author
author2 Andrade, Helena Rebelo de
Correia, Vanessa
Besselaar, Terry
Drager-Dayal, Renu
Fry, Alicia
Gregory, Vicky
Gubareva, Larisa
Kageyama, Tsutomu
Lackenby, Angie
Lo, Janice
Odagiri, Takato
Pereyaslov, Dmitriy
Siqueira, Marilda Agudo Mendonça Teixeira de
Takashita, Emi
Tashiro, Masato
Wang, Dayan
Wong, Sun
Zhang, Wenqing
Daniels, Rod S.
Hurt, Aeron C.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Meijer, Adam
Andrade, Helena Rebelo de
Correia, Vanessa
Besselaar, Terry
Drager-Dayal, Renu
Fry, Alicia
Gregory, Vicky
Gubareva, Larisa
Kageyama, Tsutomu
Lackenby, Angie
Lo, Janice
Odagiri, Takato
Pereyaslov, Dmitriy
Siqueira, Marilda Agudo Mendonça Teixeira de
Takashita, Emi
Tashiro, Masato
Wang, Dayan
Wong, Sun
Zhang, Wenqing
Daniels, Rod S.
Hurt, Aeron C.
dc.subject.en.pt_BR.fl_str_mv Influenza virus
Antiviral resistance
Neuraminidase inhibitors
Oseltamivir
Global analysis
Normalization using fold-change data
topic Influenza virus
Antiviral resistance
Neuraminidase inhibitors
Oseltamivir
Global analysis
Normalization using fold-change data
Oseltamivir
Influenza humana
Neuraminidase
esistência a Medicamentos
dc.subject.decs.pt_BR.fl_str_mv Oseltamivir
Influenza humana
Neuraminidase
esistência a Medicamentos
description National Institute for Public Health and the Environment. Bilthoven, The Netherlands.
publishDate 2014
dc.date.issued.fl_str_mv 2014
dc.date.accessioned.fl_str_mv 2015-06-17T12:05:25Z
dc.date.available.fl_str_mv 2015-06-17T12:05:25Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv MEIJER, Adam et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013. Antiviral Research, v. 110, p. 31-41, 2014.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/10882
dc.identifier.issn.pt_BR.fl_str_mv 0166-3542
dc.identifier.doi.pt_BR.fl_str_mv 10.1016/j.antiviral.2014.07.001
identifier_str_mv MEIJER, Adam et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013. Antiviral Research, v. 110, p. 31-41, 2014.
0166-3542
10.1016/j.antiviral.2014.07.001
url https://www.arca.fiocruz.br/handle/icict/10882
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/10882/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/10882/2/marilda_siqueira2etal_IOC_2014.pdf
https://www.arca.fiocruz.br/bitstream/icict/10882/3/marilda_siqueira2etal_IOC_2014.pdf.txt
bitstream.checksum.fl_str_mv 7d48279ffeed55da8dfe2f8e81f3b81f
f06f089e5e829e4c7551ddea78b9c0fc
c258ee3cf818a98496896094c6bb36ec
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813008851033653248

Registros relacionados